Ibnsina Pharma results, Q3 2022
Net profit, assets, equity and cash flow for Q3 2022, against the same period a year earlier, from the published financial statements.
Net profit30.99 millionEGP
Total assets12.35 billionEGP
Shareholders' equity1.25 billionEGP
Operating cash flow1.01 billionEGP
In short
- Ibnsina Pharma's net profit for Q3 2022 was about 30.99 million EGP.
- Total assets at the end of Q3 2022 were about 12.35 billion EGP, and shareholders' equity about 1.25 billion EGP.
- Operating cash flow for Q3 2022 was positive at 1.01 billion EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit30.99 million——
Gross profit371 million——
Total assets12.35 billion——
Total liabilities11.11 billion——
Shareholders' equity1.25 billion——
Total liabilities and equity12.35 billion——
Operating cash flow1.01 billion——
Investing cash flow-1.1 billion——
Financing cash flow247 million——
Net change in cash156 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy